Clinical Development - Oral

The foundation of research for Bimiralisib’s oral formulations currently in clinical development.

PIQUR Therapeutics AG is leading Phase I/IIa clinical development of bimiralisib oral and topical formulations for the treatment of Head and Neck Squamous Cell Carcinoma (HNSCC; oral) and Medical Dermatology (topical). This technical note describes the strong scientific foundation of compound lead optimization that has led to the development of bimiralisib’s oral application. It also introduces how research from laboratories at the University of Basel, Switzerland and the MD Anderson Cancer Center (MDACC), US is being applied by PIQUR Therapeutics AG as it develops targeted oncology medicines for the treatment of indications with a high unmet medical need.

Read More